Ann: Section 708A Notice and Appendix 2A, page-38

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 38 Last

Share
Profile

Follow
Royboy1955

501 Posts.

137

02/07/20

08:20

Post #: 45585300
Share

Originally posted by RudeeOne: ↑

Coviu spent 9 months trialing, integrating and testing ResAppDx-EU. Phenix spent 3 months trialing, integrating and testing ResAppDx-EU.
After spending all these times and resources it is unthinkable for Coviu and Phenix to sign a 2-year licensing agreement UNLESS they're both thoroughly satisfied with the efficacy of ResAppDx-EU. In addition, they must also be thoroughly satisfied with its integration to their legacy platform.

If we assume that all the above risks are mitigated, then what's left is the question of the uptake. How much annual revenue could potentially be earned through these 2 licensing agreements? Let's say Coviu and Phenix does a combined 30,000 consults per day, of which only half is GP consults. Let's say only 30% of the GP consults is respiratory related. And let's say ResApp charges $6 per use. The daily revenue comes to $27,000. This translates to $2,430,000 per quarter, or $9,720,000 per annum. Decent enough, at least for a start.

Outside Australia, we have economic evaluation pipeline with UK, German and Kenyan hospitals, and an MOU with RB. No doubt these will take time, but it's entirely reasonable to expect some eventuation by Q1 2021. In the meantime, revenue from Coviu, Phenix and SleepCheck should be sufficient to provide working cash flow for ResApp. Who knows, Asia might join the party soon.

Finally, Tony Keating coughing up $1,375,000 of his hard-earned money into converting his options is nothing but a vote of confidence in the Company. I seriously doubt he will sell them in the near future. He had that chance when the share price was much higher. He didn't take it.

Expand

You forgot the Respiratory Clinic - the free trial period finishes in September and then we can start charging

From last reports they were seeing 300 people per day @ $5 ea is around $10k per Wk or $ .5ml per year per clinic

ITs success should generate more clinics so it could be a good little money earner

RAP Price at posting: 17.5¢ Sentiment: Buy Disclosure: Held
11 Upvote

0 Great analysis

Reply

Top Stories

PIQ

Proteomics ends deal with Sonic Healthcare for US commercialisation of kidney disease test

MAY

HotCopper users liking Melbana Energy's news it's becoming an oil producer; shares jump +47%

LU7

Lithium Universe 'dream team' ready to step into the demand-supply breach in Canada

REA

UK-based Rightmove knocks back REA Group's acquisition proposal

S&P 500 futures dip during non-deciding Trump-Harris Debate; bullish for energy

There are more pages in this discussion • 95 more messages in this thread...

First 38 Last

Add RAP (ASX) to my watchlist

Ann: Section 708A Notice and Appendix 2A, page-38

Top Stories

Proteomics ends deal with Sonic Healthcare for US commercialisation of kidney disease test

HotCopper users liking Melbana Energy's news it's becoming an oil producer; shares jump +47%

Lithium Universe 'dream team' ready to step into the demand-supply breach in Canada

UK-based Rightmove knocks back REA Group's acquisition proposal

S&P 500 futures dip during non-deciding Trump-Harris Debate; bullish for energy

Featured News